In this randomized comparison of hepatitis A vaccine and immune globulin for prophylaxis after household or day-care exposure to hepatitis A, infection rates were low with either immune globulin (3.3%) or vaccine (4.4%), and the study's prespecified criterion for noninferiority was met. Hepatitis A vaccine provides long-term immunity and may be a reasonable choice for postexposure prophylaxis.

This trial of therapies for unresectable advanced head and neck cancer showed that induction chemotherapy (given before radiotherapy) with a combination of docetaxel plus the standard regimen of cisplatin and fluorouracil (TPF) was superior to the standard induction chemotherapy. Progression-free survival and overall survival were improved, and the toxicity of the triple-agent regimen was less than the toxicity of the standard regimen.

In this randomized trial, patients who had unresectable stage III or IV squamous-cell head and neck cancer with no distant metastases were assigned to receive induction treatment with docetaxel plus cisplatin and fluorouracil (TPF) or cisplatin and fluorouracil (PF) before receiving chemoradiotherapy. Patients who received TPF induction chemotherapy had significantly longer survival than did patients who received PF induction chemotherapy.

In an open-label trial, patients with type 2 diabetes with a suboptimal glycated hemoglobin level while receiving a maximally tolerated dose of metformin and sulfonylurea were randomly assigned to receive biphasic, prandial, or basal insulin. The addition of a single analogue-insulin formulation resulted in a glycated hemoglobin level of 6.5% or less in a minority of patients at 1 year. Regimens of biphasic or prandial insulin had greater efficacy than did the basal regimen but were associated with greater risks of hypoglycemia and weight gain.